Sapropterin
Sponsors
The Children's Health Council, University of California, San Diego, University of Missouri-Columbia, Children's Hospital of Philadelphia, University of Utah
Conditions
Autistic DisorderBehavioral Manifestations of Lesch-Nyhan DiseaseGTP Cyclohydrolase DeficiencyHyperphenylalaninemiaLiver CirrhosisPhenylketonuriaPhenylketonuriasPortal Hypertension
Phase 1
Phase 2
Sapropterin as a Treatment for Autistic Disorder
CompletedNCT00850070
Start: 2009-03-31End: 2011-10-31Updated: 2018-05-01
Trial of Kuvan in Lesch-Nyhan Disease
WithdrawnNCT00935753
Start: 2009-04-30End: 2010-02-28Updated: 2019-08-02
Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
CompletedNCT01456286
Start: 2011-10-31End: 2013-10-31Updated: 2013-10-07
Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria
TerminatedNCT01977820
Start: 2014-02-28End: 2014-11-30Updated: 2018-02-22
Unknown Phase
The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
CompletedNCT00964236
Start: 2009-08-31End: 2011-08-31Updated: 2018-01-04
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy
CompletedNCT00986973
Start: 2010-03-31End: 2011-09-30Updated: 2015-06-08
Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy
TerminatedNCT01541397
Start: 2011-06-30End: 2012-08-31Updated: 2015-07-07
Nutritional Status in Phenylketonuria
CompletedNCT03820804
Start: 2019-01-07End: 2019-09-10Updated: 2019-09-10